Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (Iparomlimab + Tuvonralimab) plus chemotherapy in unresectable stage III NSCLC
ChiCTR2500106888Phase 4Not yet recruiting
- Sponsor
- Huai'an First People's Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Huai'an First People's Hospital. Primary endpoint: 18-month event-free survival rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500106888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106888.